C4X Discovery Holdings Plc engages in the research and development of small molecules for immuno-inflammation. Its technologies include Conformetrix, 4sight, and PatientSeek powered by Taxonomy3. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom.